Vascepa is a prescription medication used to reduce triglyceride levels in adults with severe hypertriglyceridemia [1]. Vascepa is unique from other treatments because it contains only one active ingredient, icosapent ethyl, which is a highly purified form of eicosapentaenoic acid (EPA), one of the omega-3 fatty acids found in fish oil [2]. EPA is believed to reduce triglyceride levels by decreasing the production of very-low-density lipoprotein (VLDL) particles, which are responsible for transporting triglycerides in the blood [3]. Unlike Lovaza, another prescription medication used to reduce triglyceride levels, Vascepa does not contain docosahexaenoic acid (DHA), another omega-3 fatty acid found in fish oil. DHA has been shown to increase LDL cholesterol levels, which is a risk factor for cardiovascular disease [2]. In contrast, Vascepa has been shown to have no significant effect on LDL cholesterol levels, making it a potentially safer option for patients with cardiovascular disease or at risk for cardiovascular disease [2]. Vascepa has also been shown to reduce the risk of cardiovascular events in patients with elevated triglyceride levels and other cardiovascular risk factors [1]. Overall, Vascepa's unique composition and safety profile make it a valuable treatment option for patients with severe hypertriglyceridemia and cardiovascular risk factors.

Sources:
[1] https://www.vascepa.com/
[2] https://www.drugs.com/medical-answers/lovaza-vascepa-difference-between-3553025/
[3] https://www.drugpatentwatch.com/p/tradename/VASCEPA